Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new approach to treat advanced liver cancer, specifically a type called hepatocellular carcinoma (HCC) that has spread to nearby blood vessels. The main goal is to see if combining local treatments, like targeted radiation therapy, with immunotherapy can help patients get ready for a liver transplant. Researchers want to find out how many patients can successfully receive a transplant and how well they do five years after the procedure.

To participate, patients should be between 18 and 70 years old, weigh more than 30 kg, and have a specific type of liver cancer with certain characteristics. Participants will undergo a biopsy, receive targeted radiation therapy followed by immunotherapy over a period of up to nine months, and may be considered for a liver transplant if it’s safe for them. After the transplant, researchers will keep track of their health for five years. This trial is currently seeking volunteers, and anyone interested should check if they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-70
• • Weight \> 30 kg
• • Child Pugh Turcotte score A5 to B7
• • Macrovascular invasion (Vp1-3)
• • Total tumour volume \< 350 cm3
• • Alpha Fetoprotein \< 5000 ng/mL
• • No extrahepatic disease
• • No other contraindications to undergo a LT
• • Eastern Cooperative Oncology Group (ECOG) score 0-1
• • Capable to provide inform consent
• • Radiological and histological confirmation of hepatocellular carcinoma
• Exclusion Criteria:
• • Poorly differentiated HCC
• • Prior therapy for hepatocellular carcinoma other than liver resection or ablation
• • Portal vein tumor thrombus extending beyond main portal vein
• • Obesity class III (BMI ≥ 40 kg/m2)
• • Contraindications for radiotherapy (Y90 or SBRT) or AtezoBev